Shots:
- The EC has approved Remsima IV (100mg and 350mg vials), a liquid formulation, a biosimilar version of Remicade
- The approval is supported by data showing the liquid and powder infliximab formulations are comparable in CMC characteristics and stability after reconstitution and dilution
- The Remsima IV liquid formulation is EU-approved for all existing IV infliximab indications, including RA, adult and pediatric CD and UC, AS, PsA, and PsO
Ref: Celltrion| Image: Celltrion| Press Release
Related News:- The EC Approves Additional Presentation of Celltrion’s Omlyclo (Biosimilar, Xolair)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
